Teaching AI the languages of BioMedicine

Intelligence,
beyond the
visible.

Decades of multimodal care, synthesized into biomedical knowledge. For new medicines, intelligent devices, and a new generation of clinical decisions.

From care histories to new possibilities.40+ years of longitudinal care
01 / Decades of connected evidence

Whole-Body Spatial Intelligence

Connect observations across organs and across time, tracing each insight back to its multimodal clinical evidence.

Clinical notesRadiologyPathologyElectrophysiologyLaboratory testsGenomicsEcho videos
52M+Patient lives
40+Years of longitudinal records
18B+Radiology images
2.7B+Clinical notes
8B+Lab tests
50M+Electrophysiology waveforms
15M+Pathology images

Extraordinary science. Exceptional partners.

Meet our health system network
Mayo ClinicDuke HealthVanderbilt University Medical CenterEmory HealthcareRush University System for HealthMercy HealthCedars-Sinai Medical Center
A different way to see

The body doesn’t
work in silos.
Neither should
intelligence.

Behind every data point is a deeper story. We connect clinical notes, imaging, molecular data, and physiologic signals—across time—to help researchers see the whole picture.

01 / A richer dimension of data

Every modality.
One connected story.

Deeply curated, longitudinal data. The clinical context to see what isolated data points cannot.

Clinical notes
Illustrative scientific visualization
2.7B+

Clinical notes

Unlock unstructured clinical evidence from physician notes, reports, histories, and other narrative documentation.

Longitudinal recordsClinical contextAI curation
Go deeper into the data
Federated access. Privacy by design. Rich source-level evidence.
Explore all data
02 / The platform

Built for the questions
that move us forward.

Two powerful platforms. One purpose.
To make the complexity of biomedical data computable—and discovery possible.

nSightsFEDERATED REAL-WORLD DATA

From your next question
to your next discovery.

The real-world evidence platform for researchers who need to move from question to cohort to evidence faster.

Discover nSights
nSights clinical cohort and evidence workspace
NucleusPROPRIETARY CLINICAL INTELLIGENCE

Your data.
A new dimension of intelligence.

Connect, harmonize, and analyze your organization’s multimodal clinical data, within your own environment.

Explore Nucleus
n
Clinical trialsImagingGenomicsReal-world data
From translational discovery to clinical development and real-world evidence.Find your path
03 / Science in motion

Possibility.
Grounded in evidence.

Explore 100 publications
NeurosciencePeer-Reviewed Journal Publication

Somatosensory and peripheral neuropathic outcomes after semaglutide or tirzepatide initiation compared with other anti-diabetic medications

In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.

Biology Methods and Protocols
November 4, 2026
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
A wider field of discovery

One platform.
Many frontiers.

Clinically curated data dictionaries bring nuance to the questions that matter in each therapeutic area.

Explore every therapeutic area

Study of heart diseases, including diagnosis, treatment, and prevention of cardiovascular disorders.

Explore the data dictionary

Study of the immune system, its functions, disorders, and role in disease defense.

Explore the data dictionary

Conditions affecting a small percentage of the population, often genetic and challenging to diagnose.

Explore the data dictionary

Branch of medicine focused on the diagnosis, treatment, and research of cancer.

Explore the data dictionary

Study of diseases caused by pathogens, including bacteria, viruses, fungi, and parasites.

Explore the data dictionary

Medical specialty dealing with disorders of the nervous system, including the brain and spinal cord.

Explore the data dictionary

Branch of medicine focused on the study, diagnosis, and treatment of disorders related to the digestive system, including the stomach, intestines, liver, pancreas, and gallbladder.

Explore the data dictionary
Built on trust. Connected by science.

Extraordinary alone.
Exponential together.

Long-term partnerships with leading health systems connect deep clinical knowledge through a secure, federated AI network.

Discover our federated approach
nferenceFEDERATED
INTELLIGENCE
From intelligence to impact

Discovery that
becomes possibility.

AnumanaAnumana

Harnessing AI and translational science to decode the electrocardiogram as a predictive tool and biomarker of disease, empowering care providers to help patients early.

Explore Anumana
PramanaPramana

Enabling seamless digital adoption by pathology labs and medical centers. Created through the nference platform, Pramana is now part of Evident.

Explore Pramana
On the horizon

Ideas. Impact. Momentum.

From our newsroom
Your next question could change everything.

What will you
discover next?

Let’s find out
Voices moving science forward

Clinical perspectives.

Pause. Explore. Read the full story.
Cedars-Sinai Medical Center
Cedars-Sinai collaboration
SC

Sumeet ChughMD

Vice dean and chief artificial intelligence health research officer at Cedars-Sinai

“We expect this collaboration with nference will provide our clinicians and scientists with new ways to learn from the collective experience of patient care, help validate scientific hypotheses and accelerate biomedical discovery.”

Baim Institute for Clinical Research
MAIA & prospective trials

C. Michael GibsonMD

Professor of Medicine at Harvard and CEO of the Baim Institute for Clinical Research

“These studies from nference signal that longitudinal, AI-curated evidence can inform prospective studies in profound ways. The broad spectrum of weight-loss-independent benefits revealed by the first series of MAIA publications challenges long-held cardiometabolism assumptions that place glucose lowering and total body weight reduction at the center of therapeutic value. These findings reinforce that incretin biology is organ-specific, durable, and multidimensional.”

Duke Health
Clinical data & privacy

Craig T. AlbaneseMD, MBA

Then-Chief Executive Officer, Duke University Health System

“For example, our strategic alliance with nference aims to unlock the research potential of clinical data without ever compromising patient privacy.”

Vanderbilt University Medical Center
Vanderbilt collaboration

Jeff BalserMD, PhD

President and CEO, Vanderbilt University Medical Center; Dean, Vanderbilt University School of Medicine (at publication)

“…allows us to advance the understanding of devastating diseases while accelerating biomedical research…”

UCLA Health
Cardiovascular research

Kalyanam ShivkumarMD PhD

Distinguished Professor of Cardiology, Radiology, and Bioengineering at the University of California, Los Angeles (UCLA)

“The weighing scale may be the loudest biomarker of GLP-1 therapy effectiveness, but the heart may be reading a distinct signal of therapeutic benefit. If confirmed prospectively, this finding argues that cardiovascular trials should treat dose exposure, persistence, and organ endpoints as first-class variables rather than assuming weight loss is the major mediator.”

MaineHealth
Evidence for future trials

Clifford RosenMD

Director of the Center for Clinical & Translational Research at Maine Health and Professor at Tufts Medicine

“The recent publications from nference provide a new roadmap of AI-curated evidence that will almost certainly be used to inform gold standard randomized clinical trials for disorders beyond obesity and type 2 diabetes mellitus.”

Northwestern Medicine
Clinical-note research

Catherine C. ChengMD

Internal medicine physician, Northwestern Medicine Executive Health

“The study referenced in Medscape is fascinating: nference, an AI company that works with clinical entities to convert medical records to de-identified data, mined clinical notes for signs that patients were using retatrutide, even though it’s not FDA approved and cannot be formally prescribed (and thus not yet monitored or tracked in any accountable way).”

Mayo Clinic
Narcolepsy research

Melissa C. LipfordMD

Neurologist, Center for Sleep Medicine, Mayo Clinic; study lead author

“Understanding which comorbid conditions are most common should help clinicians better understand the challenges faced by patients with narcolepsy…”

Southcoast Health
Longitudinal weight history

Marcelo MontorziMD

Internal Medicine physician scientist at Southcoast Health

“This may be the first time that decades of body-weight history have been reconstructed from routine patient records at this scale. The finding that GLP-1 super-responders are often the same patients who experienced the most recent acceleration in weight gain is a fundamental observation. It suggests that future cardiometabolism trials should not only ask how much weight a drug reduces, but whether the patient’s prior weight-gain velocity predicts the magnitude, durability, and clinical meaning of response.”

Huntsman Cancer Institute, University of Utah
Cancer metabotyping

Manish KohliMD

Presidential Endowed Chair in Cancer Research at the University of Utah-Huntsman Cancer Institute

“For decades, oncology has studied tumor metabolism, but we have not fully leveraged the patient’s own metabolic trajectory as a clinical signal. These cancer metabotyping studies point to a common hypothesis: host metabolism may influence cancer progression, treatment tolerance, immune response, drug efficacy, and survival in ways that are measurable in routine care. If validated prospectively, weight trajectory and metabolic context could become practical tools for stratifying patients across solid tumors and hematologic malignancies.”

Johns Hopkins Medicine
Cardiometabolic dose response

Joseph SmithMD PhD

Cardiologist/Electrophysiologist, AI interventions expert and Adjunct Professor of Johns Hopkins

“The very promising link of microdose levels of these agents to lower 24-month event-rates for a broad array of cardiovascular endpoints despite very modest weight loss, when taken together with evidence of disproportionate lean muscle loss at higher doses of some agents, only emphasizes the reality that the magnitude and scope of the many and varied impacts of these agents are well beyond their effectiveness at overall weight loss.”

Duke Health
Duke collaboration

A. Eugene WashingtonMD

Then-Chancellor for Health Affairs and President and CEO, Duke University Health System

“This innovative alliance will empower our expert faculty, clinicians and staff to achieve new medical breakthroughs, share insights and knowledge…”

Mayo Clinic
Research, innovation & privacy

John D. HalamkaMD, MS

President, Mayo Clinic Platform

“…with nference, we established a secure, privacy-protecting environment that accelerates research and development of diagnostics, therapeutics and cures to improve patient care.” “To me, this is the perfect balance of agility, innovation, and privacy protection.”

Mayo Clinic
Biomedical data analytics

John D. HalamkaMD, MS

President, Mayo Clinic Platform

“Advanced technologies and biomedical data analytics from nference are accelerating our efforts to improve health for people through prevention, diagnosis, better treatments and potential cures.”

Mayo Clinic
AI-enabled electrocardiography

Paul FriedmanMD

Chair, Department of Cardiovascular Medicine, Mayo Clinic in Rochester (at publication)

“The addition of AI to the ECG … makes this approach good for patients, convenient for clinicians, and massively scalable.”

NeuTraceElectrophysiology technology

Kalyanam ShivkumarMD, PhD

NeuTrace founder; personal perspective at the time of its acquisition

“I look forward to the next-gen technologies that Anumana and nference’s combination with NeuTrace will produce.”

NeuTraceNeuTrace & Anumana

Srijoy MahapatraMD

President & Chief Operating Officer, NeuTrace (at publication)

“nFerence has done amazing work in multiple areas of medicine.”

Mayo Clinic
AI-assisted evidence curation

Andrew D. BadleyMD

Study coauthor; then enterprise chair of Molecular Medicine and the COVID-19 task force, Mayo Clinic

“We were able to quickly gather and synthesize records, tests and key patient data to efficiently report these findings.”

News-MedicalVaccination research

Tomislav MeštrovićMD, PhD

Clinical microbiologist and medical writer; Assistant Professor, University North (at publication)

“…this study (and the associated resources) highlights the positive public health effect of the vaccination campaign…”

Mayo Clinic
COVID-19 forecasting

Gianrico FarrugiaMD

President and Chief Executive Officer, Mayo Clinic (at publication)

“…really becoming better on predicting hot spots…”

Mayo Clinic
Qrativ drug discovery

Clark C. OtleyMD

Medical Director, Department of Business Development, Mayo Clinic (at publication)

“This collaboration is an example of our commitment to swiftly bring effective life-changing therapies to patients.”

Yale School of Medicine
On hair loss beyond weight loss

Mona GoharaMD

Clinical Professor of Dermatology, Yale School of Medicine

“What makes this study interesting is that even after researchers matched patients for how much weight they lost, hair loss remained somewhat more common with tirzepatide: 4.24 percent versus 3.33 percent. That suggests weight loss may not be the entire explanation.”

Mount Sinai
On how tirzepatide differs

Joshua ZeichnerMD

Director of Cosmetic and Clinical Research, Department of Dermatology, Mount Sinai Hospital

“Since the tirzepatide affects more than one receptor, it may have a greater impact on the body than just weight loss. GIP receptors have been identified in the hair follicles and, as the drug binds to these receptors, it may have an effect on the microenvironment surrounding the hair follicles, impacting their activity.”

UCLA Health
Reported perspective

Preethi SrikanthanMD

Endocrinologist and Professor of Medicine, David Geffen School of Medicine at UCLA

The reduction in lean body mass that accompanies GLP-1-induced weight loss may matter more in older patients because many start with low muscle reserve, said UCLA endocrinologist Dr. Preethi Srikanthan, who was not involved in the research. Whether tirzepatide-associated weight loss leads to clinically important frailty in vulnerable older adults needs to be verified with prospective data and gold-standard frailty assessment methods, she said.

MemorialCare
On findings in older adults

Mir AliMD

Medical Director, MemorialCare Surgical Weight Loss Center, Orange Coast Medical Center

“These conditions are rare occurrences, and we should just be more aware of the issues for older adults. By no means does it mean we should not prescribe these medications to people over 65.”

Mayo Clinic Florida
On hormone therapy and GLP-1s

Regina CastanedaMD

Lead researcher, Mayo Clinic Florida

“Interestingly, the effect was stronger with semaglutide than with tirzepatide, which deserves further study and may point to an interaction specific to GLP-1 signaling.”

Baim Institute for Clinical Research
On who keeps the weight off

C. Michael GibsonMD

Professor of Medicine at Harvard and CEO of the Baim Institute for Clinical Research

“The analysis gives us a little more hope that there are going to be some people who will not regain weight, that it’s not a lifelong treatment in everyone. We need to better identify who’s going to be successful.”

Ohio State Wexner Medical Center
On weight loss and hair loss

Susan MassickMD

Board-certified dermatologist and Professor, The Ohio State University Wexner Medical Center

“Weight loss is linked to hair loss, especially when it’s fast or dramatic”, says Susan Massick, MD, a board-certified dermatologist at The Ohio State University Wexner Medical Center. “GLP-1s are known for helping people to lose weight quickly, which can explain why some patients on tirzepatide and semaglutide were faced with hair loss.”

U.S. Food and Drug Administration
Former affiliationOn eating habits after GLP-1s

David KesslerMD

Former FDA Commissioner

“It’s not the drugs” that cause lasting weight loss, he said. “It’s whether you learn to adjust your eating while you’re on those drugs.”

Ideas are connected. Your next discovery starts here.